Menu
Search
Search
Newsroom
RDD 2022 Recap: 152a features across event agenda
2022 is a significant year for 152a (Zephex) with key commercialization milestones being met and this was seen at RDD 2022 held in Orlando Florida with a number of workshop topics and presentations featuring 152a. During the event Koura’s Dr Stuart Corr hosted a workshop for delegates which
Read more
Media
Koura launches new HFA-152a early-stage development formulation facilities in the United Kingdom
This new service will aid early-stage development formulation using the low GWP medical propellant HFA-152a. Boston, MA, USA May 14, 2021 – Koura is pleased to announce today the launch of
See Press Release
Koura awarded Platinum medal from EcoVadis for sustainability
Koura has recently been awarded a EcoVadis Platinum medal as a result of scoring in the top 1% in their sustainability assessment for our operations in the UK. As part of
See Press Release
Koura Donates 10,000 Inhalers to the Government of Maharashtra, India (Haffkine Institute)
Koura, part of Orbia Advance Corporation S.A.B. de C.V. (BMV: ORBIA*), makes a successful donation delivery of 10,000 medical grade inhalers to the Government of Maharashtra, India. The delivery of these
See Press Release
Koura announces major investment into new ‘greener’ medical propellant production facility in United Kingdom
Koura announces a multi million-pound sterling investment into a new cGMP Zephex® 152a medical propellant production facility at their Runcorn, UK location. This investment is part of a program to bring
See Press Release
‘Green’ Medical Propellant receives FDA approval to proceed to clinical trials
BOSTON, Feb. 4, 2020 – Koura (previously known as Mexichem Fluor), a pioneer in the development of next generation propellants, today announced FDA approval to proceed to clinical trials with Zephex®
See Press Release
Mexichem Fluor showcases courageous new identity
Zephex parent company, Mexichem Fluor, has unveiled a brand new corporate identity, Koura, to reflect the company’s impressive global footprint and innovative and diverse nature of its businesses. Koura’s world-leading HFA
See Press Release
Koura to supply ground breaking low-carbon footprint medical propellant to Chiesi Farmaceutici for inhalation product development and clinical trials
Landmark multi-million-pound sterling commercial agreement will advance efforts to bring Zephex®152a from the laboratory to the patient Runcorn (United Kingdom) December 2019 – Koura, the leading medical propellant manufacturer (previously known
See Press Release
Koura sanctions multi million-pound investment into Zephex® 152a facility
Leading medical propellant manufacturer and supplier, Koura, have announced a multi million-pound investment into a new laboratory facility based at their new medical division HQ at Thornton Science Park, Chester, UK.
See Press Release